Practical, evidence-based ways to manage prostate cancer: how surveillance, surgery, radiation, systemic drugs, lifestyle, and mental-health support fit together.
A concise, updated overview of prostate anatomy, detection (PSA and DRE), treatment options from active surveillance to surgery, radiation, hormone therapies, and newer targeted options for advanced disease.
Prostate cancer treatment is individualized by stage and risk. Early disease may be monitored with active surveillance or treated with surgery or radiation. Advanced disease relies on androgen-deprivation, systemic targeted agents, chemotherapy, and radioligand therapy, with decisions guided by biomarkers and patient goals.
Selecting prostate cancer treatment in 2025 means balancing tumor risk, life expectancy, and personal priorities - active surveillance is standard for many low-risk cases, while surgery, radiation, and systemic therapies remain options for higher-risk disease.
Prostate cancer is common and often asymptomatic early on. Modern screening (PSA, DRE) and diagnostics (mpMRI, targeted biopsy) allow individualized decisions - many low-risk cancers are monitored with active surveillance, while surgery, radiation, and systemic therapies treat more aggressive disease.
The PSA blood test detects prostate-specific antigen, which can be elevated for reasons besides cancer. Use PSA results with exam findings, risk factors, and additional tests. Screening involves trade-offs - benefits of early detection versus risks of overdiagnosis and biopsy complications - so discuss options with your clinician.